Literature DB >> 16126840

Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels.

Pál Kocsis1, Sándor Farkas, László Fodor, Norbert Bielik, Márta Thán, Sándor Kolok, Anikó Gere, Mónika Csejtei, István Tarnawa.   

Abstract

The spinal reflex depressant mechanism of tolperisone and some of its structural analogs with central muscle relaxant action was investigated. Tolperisone (50-400 microM), eperisone, lanperisone, inaperisone, and silperisone (25-200 microM) dose dependently depressed the ventral root potential of isolated hemisected spinal cord of 6-day-old rats. The local anesthetic lidocaine (100-800 microM) produced qualitatively similar depression of spinal functions in the hemicord preparation, whereas its blocking effect on afferent nerve conduction was clearly stronger. In vivo, tolperisone and silperisone as well as lidocaine (10 mg/kg intravenously) depressed ventral root reflexes and excitability of motoneurons. However, in contrast with lidocaine, the muscle relaxant drugs seemed to have a more pronounced action on the synaptic responses than on the excitability of motoneurons. Whole-cell measurements in dorsal root ganglion cells revealed that tolperisone and silperisone depressed voltage-gated sodium channel conductance at concentrations that inhibited spinal reflexes. Results obtained with tolperisone and its analogs in the [3H]batrachotoxinin A 20-alpha-benzoate binding in cortical neurons and in a fluorimetric membrane potential assay in cerebellar neurons further supported the view that blockade of sodium channels may be a major component of the action of tolperisone-type centrally acting muscle relaxant drugs. Furthermore, tolperisone, eperisone, and especially silperisone had a marked effect on voltage-gated calcium channels, whereas calcium currents were hardly influenced by lidocaine. These data suggest that tolperisone-type muscle relaxants exert their spinal reflex inhibitory action predominantly via a presynaptic inhibition of the transmitter release from the primary afferent endings via a combined action on voltage-gated sodium and calcium channels.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16126840     DOI: 10.1124/jpet.105.089805

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

Review 1.  Silperisone: a centrally acting muscle relaxant.

Authors:  Sándor Farkas
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

Review 2.  [Update palliative pain therapy].

Authors:  R Rolke; S Rolke; S Hiddemann; M Mücke; H Cuhls; L Radbruch; F Elsner; V Peuckmann-Post
Journal:  Internist (Berl)       Date:  2016-10       Impact factor: 0.743

3.  Human pharmacokinetics of the muscle relaxant, eperisone hydrochloride by liquid chromatography-electrospray tandem mass spectrometry.

Authors:  Barbara Melilli; Cateno Piazza; Daniela Cristina Vitale; Maria Rosa Marano; Andrea Pecori; Paolo Mattana; Valentina Li Volsi; Carmelo Iuculano; Francesco Cardì; Filippo Drago
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-03-30       Impact factor: 2.441

4.  Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress.

Authors:  Alice T Shaw; Monte M Winslow; Margaret Magendantz; Chensi Ouyang; James Dowdle; Aravind Subramanian; Timothy A Lewis; Rebecca L Maglathin; Nicola Tolliday; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-09       Impact factor: 11.205

5.  [Pain management in palliative care. Current aspects of medicinal therapy].

Authors:  H Cuhls; L Radbruch; A Brunsch-Radbruch; G Schmidt-Wolf; R Rolke
Journal:  Internist (Berl)       Date:  2013-02       Impact factor: 0.743

6.  Small Molecule Regulators of Ferroptosis.

Authors:  Sylvain Debieu; Stéphanie Solier; Ludovic Colombeau; Antoine Versini; Fabien Sindikubwabo; Alison Forrester; Sebastian Müller; Tatiana Cañeque; Raphaël Rodriguez
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Tolperisone: a typical representative of a class of centrally acting muscle relaxants with less sedative side effects.

Authors:  Stefan Quasthoff; Claudia Möckel; Walter Zieglgänsberger; Wolfgang Schreibmayer
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

8.  Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs.

Authors:  Nicholas V Cozzi; Simon D Brandt; Paul F Daley; John S Partilla; Richard B Rothman; Andreas Tulzer; Harald H Sitte; Michael H Baumann
Journal:  Eur J Pharmacol       Date:  2012-11-21       Impact factor: 4.432

9.  Basic aspects of the pharmacodynamics of tolperisone, a widely applicable centrally acting muscle relaxant.

Authors:  Kornelia Tekes
Journal:  Open Med Chem J       Date:  2014-07-11

10.  Development and Validation of a Precise, Single HPLC Method for the Determination of Tolperisone Impurities in API and Pharmaceutical Dosage Forms.

Authors:  Thummala Veera Raghava Raju; Raja Kumar Seshadri; Srinivas Arutla; Tharlapu Satya Sankarsana Jagan Mohan; Ivaturi Mrutyunjaya Rao; Someswara Rao Nittala
Journal:  Sci Pharm       Date:  2012-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.